Gene expression profiling is considered **investigational** for **either** of the following:
- To evaluate the site of origin of a tumor of unknown primary
- To distinguish a primary from a metastatic tumor

### Policy Guidelines

#### Genetics Nomenclature Update

The Human Genome Variation Society (HGVS) nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG1). The Society’s nomenclature is recommended by the Human Variome Project, the Human Genome Organization (HUGO), and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology—“pathogenic,” “likely pathogenic,” “uncertain significance,” “likely benign,” and “benign”—to describe variants identified that cause Mendelian disorders.

**Table PG1. Nomenclature to Report on Variants Found in DNA**

<table>
<thead>
<tr>
<th>Previous</th>
<th>Updated</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mutation</td>
<td>Disease-associated variant</td>
<td>Disease-associated change in the DNA sequence</td>
</tr>
<tr>
<td>Variant</td>
<td>Change in the DNA sequence</td>
<td></td>
</tr>
<tr>
<td>Familial variant</td>
<td>Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives</td>
<td></td>
</tr>
</tbody>
</table>

**Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification**

<table>
<thead>
<tr>
<th>Variant Classification</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathogenic</td>
<td>Disease-causing change in the DNA sequence</td>
</tr>
<tr>
<td>Likely pathogenic</td>
<td>Likely disease-causing change in the DNA sequence</td>
</tr>
<tr>
<td>Variant of uncertain significance</td>
<td>Change in DNA sequence with uncertain effects on disease</td>
</tr>
<tr>
<td>Likely benign</td>
<td>Likely benign change in the DNA sequence</td>
</tr>
<tr>
<td>Benign</td>
<td>Benign change in the DNA sequence</td>
</tr>
</tbody>
</table>

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

#### Genetic Counseling

Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substance and may reduce inappropriate testing; further, genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.
The following CPT code is specific for the PathWork Tissue of Origin® Test:

- **81504**: Oncology (tissue of origin), microarray gene expression profiling of >2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores

The following CPT code is specific to the CancerTYPE ID® test:

- **81540**: Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype

The other tests described in this policy do not have specific CPT codes. If the test result is calculated using an algorithm and reported as a numeric score(s) or as a probability, the following CPT code would be reported:

- **81599**: Unlisted multianalyte assay with algorithmic analysis

If the test result is NOT calculated using an algorithm and reported as a numeric score(s) or as a probability, the following CPT code would be reported:

- **81479**: Unlisted molecular pathology procedure

### Description

Cancers of unknown primary represent 3% to 4% of cancers diagnosed in the United States. These cancers are heterogeneous and many accompanied by poor prognoses. A detailed history and physical combined with imaging and tissue pathology can identify some, but not all, primary sources of secondary tumors. It is suggested that identifying the likely primary source with gene expression profiling to direct treatment may improve health outcomes.

### Related Policies

- N/A

### Benefit Application

Benefit determinations should be based in all cases on the applicable contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

Some state or federal mandates (e.g., Federal Employee Program [FEP]) prohibits plans from denying Food and Drug Administration (FDA)-approved technologies as investigational. In these instances, plans may have to consider the coverage eligibility of FDA-approved technologies on the basis of medical necessity alone.

### Regulatory Status

In 2008, the PathWork® Tissue of Origin Test™ (Response Genetics; now Cancer Genetics) was cleared for marketing with limitations (see below) by the U.S. Food and Drug Administration (FDA) through the 510(k) process (FDA product code: OIW), with subsequent clearances for expanded applications in 2010 and minor modifications in 2012. The FDA determined that the test was substantially equivalent to existing tests for use in measuring the degree of similarity between the RNA expression pattern in a patient's fresh-frozen tumor and the RNA expression...
patterns in a database of tumor samples (poorly differentiated, undifferentiated, metastatic cases) that were diagnosed according to current clinical and histopathologic practice.

Limitations to the clearance were as follows:

- The PathWork® Tissue of Origin Test is not intended to establish the origin of tumors that cannot be diagnosed according to current clinical and pathologic practice (e.g., a cancer of unknown primary).
- It is not intended to subclassify or modify the classification of tumors that can be diagnosed by current clinical and pathologic practice or to predict disease course, or survival or treatment efficacy, or to distinguish primary from metastatic tumor.
- Tumor types not in the PathWork® Tissue of Origin Test database may have RNA expression patterns similar to RNA expression patterns in tumor types in the database, leading to indeterminate results or misclassifications.

The test is now offered by Cancer Genetics, as the Tissue of Origin® test.

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). CancerTYPE ID® (Biotheranostics, San Diego, CA) are miRview® (or RosettaGX Cancer Origin™; Rosetta Genomics, Philadelphia, PA) are available under the auspices of the CLIA. Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing. To date, the FDA has chosen not to require any regulatory review of this test.

**Rationale**

**Background**

**Cancers of Unknown Primary**

Cancers of unknown primary, or occult primary malignancies, are tumors that have metastasized from an unknown primary source; they make up about 3% of all cancers in the United States.\(^1\)

Most cancers of unknown primary are adenocarcinomas or undifferentiated tumors; less commonly, they may be squamous carcinomas, melanoma, soft tissue sarcoma, or neuroendocrine tumors. Osteo- and chondrosarcomas rarely produce cancers of unknown primary. The most common primary sites of cancers of unknown primary are lung and pancreas, followed by colon and stomach, then breast, ovary, prostate, and solid-organ carcinomas of the kidney, thyroid, and liver. Conventional methods used to aid in the identification of the origin of a cancer of unknown primary include a thorough history and physical examination; computed tomography scans of the chest, abdomen, and pelvis; routine laboratory studies; and targeted evaluation of specific signs and symptoms.\(^2\)

**Diagnosis and Classification**

Biopsy of a cancer of unknown primary with detailed pathology evaluation may include immunohistochemical analysis of the tumor. Immunohistochemical identifies different antigens present in different types of tumors and can usually distinguish an epithelial tumor (i.e., carcinoma) from melanoma or sarcoma. Detailed cytokeratin panels often allow further classification of carcinoma; however, tumors of different origins may show overlapping cytokeratin expression. Results of immunohistochemical may provide a narrow differential of possible sources of a tumor's origin, but not necessarily a definitive answer.

Recent advances in the understanding of gene expression in normal and malignant cells have led researchers to explore molecular classification to improve the identification of the site of origin of a cancer of unknown primary. The molecular classification of cancers is based on the premise that, despite different degrees of loss of differentiation, tumors retain sufficient gene expression “signatures” as to their cell of origin, even after metastasis. Theoretically, it is possible
to build a gene expression database spanning many different tumor types to compare to the expression profile of very poorly differentiated tumors or a cancer of unknown primary to aid in the identification of the tumor type and organ of origin. The feasibility of using molecular classification schemes with gene expression profiling to classify these tumors of uncertain origin has been demonstrated in several studies. 3, 4, 5, 6.

**Tissue of Origin Testing, Treatment Selection, and Health Outcomes**

About 80% of patients with cancer of unknown primary have a poor prognosis with a median survival of 3 to 10 months. 7, 8, 9, 10, 11 Multiple sites of involvement are observed in about 50% of patients, commonly in the lungs, liver, bones, and lymph nodes. The premise of tissue of origin testing in cancers of unknown primary is that identifying a likely primary tumor site will inform treatment selection leading to improved survival and other outcomes or as a predictive test. To evaluate whether treatment selection can be improved, the ability of a test to suggest a likely site of origin (clinical validity) must be first be shown. But demonstrating clinical validity may be problematic because patients with cancers of unknown primary have no identified primary tumor for a reference standard. Imperfect reference standards must be relied on such as the available presumptive or a reference pathologic diagnosis, known tumor types, or comparisons immunohistochemical. A primary tumor diagnosed during follow-up might also be used as a reference standard, but its use would be subject to potential selection bias. Therefore, even substantial evidence supporting the ability of a test to suggest a likely site of origin will be insufficient to infer benefit. Convincing evidence for benefit requires demonstrating that using a test to select treatment will improve outcomes.

**Tests Reviewed in This Report**

Evidence on the clinical validity and clinical utility for 3 gene expression profiling tests is reviewed herein (see Table 1).

**Table 1. Gene Expression Profiling Tests for Cancers of Unknown Primary**

<table>
<thead>
<tr>
<th>Test</th>
<th>Manufacturer</th>
<th>Platform</th>
<th>Genes Assayed, n</th>
<th>Tumor Types Assessed, n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tissue of Origin</td>
<td>Cancer Genetics</td>
<td>Oligonucleotide microarray</td>
<td>2000</td>
<td>15</td>
</tr>
<tr>
<td>CancerTYPE ID</td>
<td>Biotheranostics</td>
<td>RT-qPCR</td>
<td>92</td>
<td>54</td>
</tr>
<tr>
<td>RosettaGX Cancer Origin</td>
<td>Rosetta Genomics</td>
<td>RT-qPCR (microRNA)</td>
<td>64</td>
<td>49</td>
</tr>
</tbody>
</table>

Adapted from Agwa et al (2013). 8, 9

RT-qPCR: real-time quantitative polymerase chain reaction.

a Formerly PathWork and ResponseDX: Tissue of Origin.

b Formerly miRview met2.

The Tissue of Origin test (formerly known as the PathWork Tissue of Origin Test and ResponseDX: Tissue of Origin; Cancer Genetics) measures the expression of 2000 genes and compares the similarity of the gene expression profiling of a cancer of unknown primary with a database of known profiles from 15 tissues with more than 60 histologic morphologies. The report generated for each tumor comprises a “similarity score,” which is a measure of similarity of gene expression profiling of the specimen to the profile of the 15 known tumors in the database. Scores range from 0 (very low similarity) to 100 (very high similarity), and sum to 100 across all 15 tissues on the panel. If a single similarity score is 30 or more, it indicates that this is likely the tissue of origin. If every similarity score is between 5 and 30, the test result is considered indeterminate, and a similarity score of less than 5 rules out that tissue type as the likely origin. PathWork Diagnostics developed the test but filed for bankruptcy in early 2013; Response Genetics purchased its assets, and it, in turn, was acquired by Cancer Genetics in late 2015.

An alternative method to measure gene expression is real-time quantitative polymerase chain reaction. Real-time quantitative polymerase chain reaction can be used at the practice level; however, it can only measure, at most, a few hundred genes, limiting tumor categorization to 7 or fewer types. Tumor classification accuracy rates using real-time polymerase chain reaction have been reported to be as high as 87%, but lower (71%) the more undifferentiated the tumor
Gene Expression-Based Assays for Cancers of Unknown Primary

One assay that uses real-time quantitative polymerase chain reaction is the CancerTYPE ID (Biotheranostics) assay, which measures the expression of messenger RNA in a CUP tissue sample. Samples for this are formalin-fixed, paraffin-embedded tissue sections or unstained 10 mm sections on glass slides. Expression levels of 92 genes (87 tumor-associated genes and 5 reference genes for normalization) are used to detect 27 tumor types in a known database of 578 tumors with a range of 5 to 49 tumors per type. The report generated is the probability for the main cancer type, possible subtypes, tumor types not able to be excluded, and those ruled out with 95% confidence calculated by K nearest neighbor analysis.

miRview mets is another real-time quantitative polymerase chain reaction test that uses microRNAs (miRNA), small noncoding, single-stranded RNA molecules that regulate genes posttranscription, as a signature for tumor differentiation. Expression levels of these miRNAs have been shown to be a sensitive biomarker across various pathologic conditions. Samples for this test are formalin-fixed, paraffin-embedded tissue. The miRview test used 48-panel markers to detect 22 tumor types in a known database of 336 tumors, with a range of 1 to 49 tumors per type. Results from the test provided a tumor of origin but may list multiple possibilities calculated by a binary decision tree and K nearest neighbor algorithm. A second-generation test, the RosettaGX Cancer Origin Test (formerly miRview mets2 and ProOnc Tumor Source), has also been developed; this test expands the number of tumor types to 49 primary origins with a panel of 64 miRNAs.

Literature Review
Evidence reviews assess whether a medical test is clinically useful. A useful test provides information to make a clinical management decision that improves the net health outcome. That is, the balance of benefits and harms is better when the test is used to manage the condition than when another test or no test is used to manage the condition.

The first step in assessing a medical test is to formulate the clinical context and purpose of the test. The test must be technically reliable, clinically valid, and clinically useful for that purpose. Evidence reviews assess the evidence on whether a test is clinically valid and clinically useful. Technical reliability is outside the scope of these reviews, and credible information on technical reliability is available from other sources.

Gene Expression Profiling Tests for Cancers of Unknown Primary
Clinical Context and Test Purpose
The purpose of tissue of origin testing is to identify a likely primary tumor type and by doing so inform treatment selection that might lead to improved health outcomes (i.e., as a predictive test).

Patients
The target populations are patients with a cancer of unknown primary and no identified primary tumor following a standard evaluation (e.g., history, physical, imaging, pathology).

Interventions
Three gene expression profiling tests currently available in the United States are the primary focus of this review: Tissue of Origin, CancerTYPE ID, and RosettaGX Cancer Origin (see Table 1).

Comparators
The comparator of interest is standard of care management based on tumor type and probable site of origin (i.e., usual care without gene expression profiling).

Outcomes
Although test validity is relevant as a premise of the test, the outcomes informative of potential benefit include overall survival, disease-specific survival, progression-free survival, and quality of life.
Given the generally poor survival experience of patients with cancer of unknown primary, outcomes assessed over a follow-up of 1 to 2 years are relevant.

**Simplifying Test Terms**

There are 3 core characteristics for assessing a medical test. Whether imaging, laboratory, or other, all medical tests must be:

- Technically reliable
- Clinically valid
- Clinically useful.

Because different specialties may use different terms for the same concept, we are highlighting the core characteristics. The core characteristics also apply to different uses of tests, such as diagnosis, prognosis, and monitoring treatment.

Diagnostic tests detect presence or absence of a condition. Surveillance and treatment monitoring are essentially diagnostic tests over a time frame. Surveillance to see whether a condition develops or progresses is a type of detection. Treatment monitoring is also a type of detection because the purpose is to see if treatment is associated with the disappearance, regression, or progression of the condition.

Prognostic tests predict the risk of developing a condition in the future. Tests to predict response to therapy are also prognostic. Response to therapy is a type of condition and can be either a beneficial response or an adverse response. The term predictive test is often used to refer to response to therapy. To simplify terms, we use prognostic to refer both to predicting a future condition or to predicting a response to therapy.

**Technically Reliable**

Assessment of technical reliability focuses on specific tests and operators and requires review of unpublished and often proprietary information. Review of specific tests, operators, and unpublished data are outside the scope of this evidence review, and alternative sources exist. This evidence review focuses on the clinical validity and clinical utility.

**Clinically Valid**

A test must detect the presence or absence of a condition, the risk of developing a condition in the future, or treatment response (beneficial or adverse).

Specifically, for these tests, clinical validity is the ability of a test to determine the site of origin. Demonstrating clinical validity is complicated by the lack of reference standard. Imperfect reference standards must be relied on such as the available presumptive or a reference pathologic diagnosis, known tumor types, comparisons immunohistochemistry or primary tumor diagnosed during follow-up.

**Tissue of Origin Test**

Five included studies reported evidence that the Tissue of Origin Test can predict a likely site of origin using a variety of reference standards: reference or available diagnosis, a primary tumor identified during follow-up, and immunohistochemical. Concordance rates in the range of 85% to 90% were reported compared with the reference standards employed.

The clinical validation study for the PathWork Tissue of Origin Test submitted to the U.S. Food and Drug Administration (FDA) in 2008 compared gene expression profiling tests for 25 to 69 samples with each of the 15 known tumors on the PathWork panel (mean, 36 specimens per known tumor). Specimens included poorly differentiated, undifferentiated, and metastatic tumors. A similarity score was assigned to 545 specimens and then compared with the available specimen diagnosis. Based on the 545 results, the probability that a true tissue of origin call was obtained when a similarity score of 30 or more was reported was 93% (95% confidence interval, 90% to 95%), and the probability that a true-negative tissue call was made when a similarity score of 5
or less was reported was 100% (95% confidence interval, 100% to 100%). Overall PathWork performance comparing the profiles of the 545 specimens with the panel of 15 known tumor types showed a positive percent agreement of 90% (95% confidence interval, 87% to 92%), negative percent agreement of 100% (95% confidence interval, 99% to 100%), nonagreement of 6% (95% confidence interval, 4% to 9%), and indeterminate of 4% (95% confidence interval, 3% to 7%).

The clinical validation study for the PathWork Tissue of Origin Test Kit formalin-fixed, paraffin-embedded submitted to the FDA in 2009 compared gene expression profiling results for 25 to 57 samples with each of the 15 known tumors on the PathWork panel (mean, 31 specimens per known tumor). Specimens included poorly differentiated, undifferentiated, and metastatic tumors. A similarity score was assigned to 462 specimens and then compared with the available specimen diagnosis. Based on the 462 results, the probability that a true tissue of origin call was obtained when a similarity score was reported (positive percent agreement) was 89% (95% confidence interval, 85% to 91%), and the probability that a true negative (i.e., unknown) tissue call was made when a similarity score of 5 or less was reported (negative percent agreement) was 99% (95% confidence interval, 98% to 100%). The proportion of nonagreement (false-negatives) was 12% (95% confidence interval, 9% to 15%). Further details of these data are available in the FDA’s decision summary.

Monzon et al (2009) conducted a multicenter, blinded validation study of the PathWork test. Specimens included poorly differentiated, undifferentiated, and metastatic tumors. A total of 351 frozen specimens and electronic files of microarray data on 271 specimens were obtained, with 547 meeting all inclusion criteria. A similarity score was given to the specimens, which was then compared with the original pathology report that accompanied the specimen. The PathWork performance comparing the profiles of the 547 specimens with the panel of 15 known tumor types showed overall sensitivity (positive percent agreement with reference diagnosis) of 88% (95% confidence interval, 85% to 90%) and overall specificity (negative percent agreement with reference diagnosis) of 99% (95% confidence interval, 98% to 100%), with the original pathology report acting as the reference standard. The authors noted that because there was no independent confirmation of the original pathology, using the pathology reports as the reference standard could introduce error into study results. Agreement differed by cancer type: 94% for breast and 72% for both gastric and pancreatic; these differences were statistically significant (p=0.04). Agreement between the test result and reference diagnosis varied by the testing center: 88%, 84%, 92%, and 90% for Clinical Genomics facility, Cogenics, Mayo Clinic, and the International Genomics Consortium, respectively (differences not statistically significant).

Azueta et al (2013) compared immunohistochemical in formalin-fixed, paraffin-embedded tissue with the PathWork test in archived fresh-frozen tissue in a series of 32 metastatic tumors of suspected gynecologic origin (25 metastatic to the ovary, 7 peritoneal metastases). The primary site of origin was determined by clinical follow-up in 29 (83%) patients and was considered the criterion standard. All peritoneal metastases originated from the ovary, and metastases to the ovary originated from the colon (11 cases), breast (5 cases), stomach (4 cases), endometrium (1 case), and an angiosarcoma (1 case). Eligible frozen sections from these cases and 3 with cancer of unknown primary were required to contain at least 60% tumor and less than 20% necrotic tissue. PathWork concordance was 86% (25/29 diagnoses); in 2 cases, diagnoses were incorrect, and 2 cases had 2 possible diagnoses. PathWork diagnosed 2 of 3 cases of the unknown primary after clinical follow-up. Immunohistochemical concordance was 79% (23/29 diagnoses); 4 cases were indeterminate, and 2 cases had 2 possible diagnoses; diagnoses of 2 of 3 cases of the unknown primary after clinical follow-up matched the PathWork diagnoses.

Handorf et al (2013) reported on a clinical validation study of formalin-fixed, paraffin-embedded metastatic cancer specimens of known primary tumors representing the 15 tissue types on the PathWork test panel. PathWork’s diagnostic performance was compared with immunohistochemical in 160 tumor samples. Overall concordance with known diagnoses (i.e.,
accuracy) was 89% for PathWork vs 83% for immunohistochemical (p = 0.013). In 51 poorly
differentiated and undifferentiated tumors, PathWork accuracy was 94% and
immunohistochemical accuracy was 79% (p = 0.016). In 106 well-differentiated and moderately
differentiated tumors, PathWork and immunohistochemical performance were similar (87% and
85% accuracy, respectively; p = 0.52). These results are based on 157 specimens for which
both PathWork and immunohistochemical testing were performed; 3 specimens from the original
set of 160 were considered nonevaluable by PathWork (similarity score < 20) and were
excluded.

**CancerTYPE ID**

Results derived from 4 studies reported evidence for supporting the ability of CancerTYPE ID to
predict a likely site of origin. Reference standards included a known tumor type, reference
diagnosis, a primary tumor identified during follow-up, and immunohistochemical. Reported
sensitivities varied according to tumor type generally ranged from 80% to over 90%.

Erlander et al (2011) revised the original classifier algorithm using 2,206 samples derived from
multiple tumor banks and commercial sources. These samples expanded on the standard
CancerTYPE ID algorithm to increase tumor coverage and depth across 30 main cancer types
and 54 histologic subtypes. Sensitivity of the classifier for the main cancer type based on internal
validation (leave-one-out cross-validation) was 87% (95% confidence interval, 85% to 88%) and,
for the histologic subtype, 85% (95% confidence interval, 83% to 86). In an independent test set
of 187 samples, sensitivity was 83% (95% confidence interval, 78% to 88%).

Kerr et al (2012) reported on a multicenter study of the 92-gene CancerTYPE ID test conducted
to assess the test's clinical validity. Approximately half of formalin-fixed, paraffin-embedded
specimens for this study were from metastatic tumors of any grade, and the remainder from
poorly differentiated primary tumors processed within 6 years of testing. Laboratory personnel
at 3 study sites, blinded to all information except biopsy site and patient sex, performed
diagnostic adjudication on 790 tumors, across 28 tumor types. Each specimen was then
classified by class or main type and subtype with the 92-gene assay. A similarity score of 85% or
greater was specified a priori as a threshold for classification, with cases falling below this value
determined to be unclassifiable by the test. When results of the 92-gene test were compared
with adjudicated diagnoses, the overall sensitivity of the 92-gene assay was 87% (95% confidence
interval, 84% to 89%) with a range of 48% to 100% within tumor types. The reference
diagnosis was incorrectly ruled out in 5% of cases, and 6% remained unclassifiable. Test
specificity was uniformly high in all tumor types, ranging from 98% to 100%. Positive predictive
values ranged from 61% to 100% and exceeded 90% in 16 of 28 tumor types. In an analysis of
covariance, assay performance was found to be unaffected by tissue type (i.e., metastatic or
primary), histologic grade, or specimen type. A 2014 subgroup study of this dataset evaluated
primary (41%) and metastatic (59%) tumors considered to have neuroendocrine differentiation
(Merkel cell carcinoma, medullary thyroid carcinoma, pheochromocytoma, paraganglioma,
pumonary neuroendocrine carcinoma, gastrointestinal neuroendocrine carcinoma, and
pancreatic neuroendocrine carcinoma). For 75 included tumors, assay sensitivities were 99% (95% confidence interval, 93% to 99%) for classification of neuroendocrine tumor type (e.g.,
neuroendocrine, germ cell) and 95% (95% confidence interval, 87% to 98%) for subtype (site of
origin). Positive predictive values ranged from 83% to 100% for individual subtypes. A report by
Brachtel et al (2016) examined a subset of 109 patients with limited tissue studied by Kerr et
al (2012) and 644 other consecutive cytology samples. In the 109 patients, sensitivity for tumor
classification was 91% (95% CI, 84% to 95%), consistent with the larger sample. From the 644
cases, a sensitivity of 87% (95% confidence interval, 84% to 89%) was estimated.

Greco et al (2013) published a retrospective, single-center study of 171 patients diagnosed with
cancer of unknown primary after a clinical diagnostic workup (i.e., before
immunohistochemical). The study evaluated the accuracy of gene expression profiling
(CancerTYPE ID) by verifying results with latent primary tumor sites found months after initial
presentation (24 patients) or with immunohistochemical and/or clinicopathologic findings (147
patients). Minimum test performance thresholds were prespecified. Tumor specimens adequate for gene expression profiling were obtained in 149 (87%) patients, and diagnoses were made in 144 (96%). Of 24 patients with latent primary tumor sites, CancerTYPE ID diagnoses were accurate in 18 (75%), and IHC diagnoses were accurate in 6 (25%). Of 52 patients with the diagnosis made by immunohistochemical testing and subsequent gene expression profiling, diagnoses matched in 40 (77%). When immunohistochemical suggested 2 or 3 possible primary sites (97 patients), CancerTYPE ID diagnosis matched one of the proposed diagnoses in 43 (44%). Among 35 patients with discordant immunohistochemical and CancerTYPE ID diagnoses, clinicopathologic correlates and subsequent immunohistochemical supported the CancerTYPE ID diagnoses in 26 (74%). The authors concluded that gene expression profiling “complements standard pathologic evaluation” of cancer of unknown primary.

Consistent with other clinical validity data, Greco et al (2015) retrospectively reported on the use of CancerTYPE ID on archived samples from 30 patients with cancer of unknown primary and poorly differentiated neoplasms. This subset of patients with cancer of unknown primary is considered potentially treatment sensitive but comprised a small number (4%) of the 751 cancer of unknown primary patients evaluated from 2000 through 2012 at Tennessee centers. A primary site was identified in 2 patients. A diagnosis was assigned by gene expression profiling in 25 (83%) of the samples. Although 7 recently evaluated patients received treatment based on the diagnosis provided, and 5 reportedly had “favorable” outcomes, whether the benefit was obtained cannot be assessed.

RosettaGX Cancer Origin
Meiri et al (2012) assessed the clinical validity of the miRview mets2 test in 509 formalin-fixed, paraffin-embedded specimens. Four hundred eighty-nine of these samples were successfully processed, and results were compared with the known origin of the specimen. The sensitivity was 86% and specificity exceeded 99%. Three smaller clinical validation studies testing 83 to 204 samples reported similar sensitivity and specificity, with ranges of 84% to 86% and 95% to 99%, respectively.

Section Summary: Clinically Valid
Using different reference standards, these tests have reported sensitivities or concordances generally high (e.g., 80% to 90% or more). However, clinical validity evidence does not provide support for potential benefit.

Clinically Useful
A test is clinically useful if the use of the results informs management decisions that improve the net health outcome of care. The net health outcome can be improved if patients receive correct therapy, or more effective therapy, or avoid unnecessary therapy, or avoid unnecessary testing.

Direct Evidence
Direct evidence of clinical utility is provided by studies that have compared health outcomes for patients managed with and without the test. Because these are intervention studies, the preferred evidence would be from randomized controlled trials (RCTs). One published RCT and one conference presentation have been identified.

Hayashi et al (2019) randomized 130 patients with cancer of unknown primary to gene expression profiling directed therapy based on the predicted tissue of origin or to empirically-directed chemotherapy with paclitaxel and carboplatin (see Table 1). A total of 101 patients received the assigned treatment and were included in the analysis. There was no significant difference between the two groups in the 1-yr survival rate, overall survival, or progression-free survival (see Table 2). For example, the 1-year survival rate was 44.0% for patients who received gene expression profiling directed treatment and 54.9% for patients who received empirical chemotherapy (P =.264). The identification of more-responsive and less-responsive tissue types was prognostic for overall survival, (16.7 vs 10.6 months; p =.116) and progression-free survival (5.5
vs 3.9 months; p = 0.018), both respectively. There were several limitations to this trial which included the high percentage of patients who did not receive the assigned treatment (see Tables 3 and 4). A major limitation in interpretation of these results is that during the trial period there were few treatments that were site specific, so there was minimal difference in the actual treatments given to the two groups.

The second is the Randomised Phase III Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With Carcinoma of an Unknown Primary (CUP) (GEFCAPI 04) study that was presented at the 2019 Congress of the European Society for Medical Oncology in Barcelona. The majority of patients in the experimental group were assessed with Cancer TYPE ID. For the entire group of experimental and control patients analyzed (n=223), there was no significant difference in overall survival (hazard ratio: 0.92, p=0.71) or progression-free survival (hazard ratio: 0.95, p=0.71) between patients who received site-directed therapy or empirically directed therapy of cisplatin and gemcitabine. There were 60 patients who had a gene expression profiling test with a predicted site of origin that was likely to be insensitive to cisplatin and gemcitabine, among whom overall survival for the site-directed and control groups was also not significantly different (hazard ratio: 0.74, p=0.33). However, the study was underpowered for this subgroup analysis. Median overall survival in the subgroup was not improved by gene expression profiling testing 9.1 mo [95% confidence interval: 5.65; 14.62] compared to the control group 10.87 mo [95% confidence interval: 3.45; 11.73]. As in the study by Hayashi et al, using a molecular test followed by tailored systemic treatment did not improve outcomes in the total population of patients with cancer of unknown primary.

Table 2. Summary of Key RCT Characteristics

<table>
<thead>
<tr>
<th>Study, Trial</th>
<th>Countries</th>
<th>Sites</th>
<th>Dates</th>
<th>Participants</th>
<th>Active</th>
<th>Comparator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hayashi et al (2019)</td>
<td>Japan</td>
<td>14</td>
<td>2008-2017</td>
<td>Patients with CUP (130 who were randomized and had sufficient tissue for analysis)</td>
<td>GEP-directed therapy (50 analyzed)</td>
<td>Empirically directed chemotherapy with PC (51 analyzed)</td>
</tr>
<tr>
<td>Fizazi et al (2019)</td>
<td>Europe</td>
<td>4</td>
<td>2012-2019</td>
<td>Patients with CUP (243)</td>
<td>GEP-directed therapy (110 mITT)</td>
<td>Empirically directed chemotherapy with CG (113 mITT)</td>
</tr>
</tbody>
</table>

CG: cisplatin and gemcitabine; CUP: cancer of unknown primary; mITT: modified intent to treat; PC: paclitaxel and carboplatin; RCT: randomized controlled trial.

Table 3. Summary of Key RCT Results

<table>
<thead>
<tr>
<th>Study</th>
<th>1-yr Survival Rate</th>
<th>Overall Survival (95% CI) mo</th>
<th>Progression Free Survival (95% CI) mo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hayashi et al (2019)</td>
<td>44.0%</td>
<td>9.8 (5.7 to 13.8)</td>
<td>5.1 (1.9 to 8.3)</td>
</tr>
<tr>
<td>N</td>
<td>101</td>
<td>101</td>
<td>101</td>
</tr>
<tr>
<td>GEP-directed therapy</td>
<td>54.9%</td>
<td>12.5 (8.9 to 16.1)</td>
<td>4.8 (3.3 to 6.5)</td>
</tr>
<tr>
<td>Empirical PC</td>
<td>0.264</td>
<td>0.896</td>
<td>0.550</td>
</tr>
<tr>
<td>HR (95% CI)</td>
<td>1.028 (0.678 to 1.560)</td>
<td>0.884 (0.590 to 1.326)</td>
<td></td>
</tr>
<tr>
<td>p-Value</td>
<td>0.096</td>
<td>0.550</td>
<td></td>
</tr>
<tr>
<td>Fizazi et al (2019)</td>
<td>92 (0.69-1.23)</td>
<td>0.95 (0.72-1.25)</td>
<td></td>
</tr>
<tr>
<td>N</td>
<td>223</td>
<td>223</td>
<td></td>
</tr>
<tr>
<td>HR (95% CI)</td>
<td>0.71</td>
<td>0.71</td>
<td></td>
</tr>
<tr>
<td>p-Value</td>
<td>0.71</td>
<td>0.71</td>
<td></td>
</tr>
</tbody>
</table>

CI: confidence interval; HR: hazard ratio; RCT: randomized controlled trial.

Table 4. Relevance Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes</th>
<th>Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hayashi et al (2019)</td>
<td>4. There were few treatments available at the time of the study that were site specific, resulting in little difference between the site specific and empiric chemotherapy treatments</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The study limitations stated in this table are those notable in the current review; this is not a comprehensive limitations assessment.

- **Population key:** 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.
- **Intervention key:** 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest.
- **Comparator key:** 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.
- **Outcomes key:** 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not establish and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.
- **Follow-Up key:** 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

### Table 5. Study Design and Conduct Limitations

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocationa</th>
<th>Blindingb</th>
<th>Selective Reportingc</th>
<th>Data Completenessd</th>
<th>Powere</th>
<th>Statisticalf</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hayashi et al (2019)</td>
<td>4. Following randomization, if the assay was completed but the results could not predict a tissue of origin, patients were transferred to the empiric treatment arm.</td>
<td>1, 2, 3. No blinding</td>
<td>1. There was high loss to follow-up with 29 patients who did not receive the assigned therapy and were not included in the analysis</td>
<td>2. There was insufficient power due to the high loss to follow-up.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The study limitations stated in this table are those notable in the current review; this is not a comprehensive limitations assessment.

- **Allocation key:** 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.
- **Blinding key:** 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.
- **Selective Reporting key:** 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.
- **Data Completeness key:** 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).
- **Power key:** 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.
- **Statistical key:** 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

### Tissue of Origin Test

Nyström et al (2012) enrolled 65 physicians (from 316 approached) caring for 107 patients with cancer of unknown primary in 2009 to participate in a study of management changes following a tissue of origin test. Prior to the test, physicians had no suspected diagnosis for 54 (41%) patients, which declined to 17 (16%) after testing. Changes in management were reported in 70 (65%) patients. Physicians reported test results were helpful with regard to diagnosis, choosing therapy, and triaging. Median survival was 14 months, which the authors suggested was longer than 9 months for unselected chemotherapy treated cancer of unknown primary patients. However, the low physician participation rate and lack of a concurrent comparator group limit any implications of these results. The study was supported by PathWork Diagnostics and 2 authors company employees.

Yoon et al (2016) reported on results of a multicenter phase 2 trial evaluating combined use of carboplatin, paclitaxel, and everolimus in patients with cancer of unknown primary. The primary outcome was an objective response, and the study’s 2-stage design with 11 or more responses in 50 assessable patients at the second stage considered success. There were 16 partial responses (objective response rate, 36% 95% confidence interval, 22% to 51%). Results from the PathWork Tissue of Origin Test were used post hoc to examine any association with response to therapy. In 38 of 46 patients, the test was successfully obtained, and 10 different tissues of origin were
predicted. In 19 patients with a tissue of origin where platinum/taxane therapy might be considered standard therapy, objective response rates were higher compared with other patients (53% vs 26%, p = 0.097), accompanied by longer progression-free survival (6.4 months vs 3.5 months, p = 0.026; hazard ratio, 0.47; 95% CI, 0.24 to 0.93), and longer overall survival (median, 17.8 months vs 8.3 months; p = 0.005; hazard ratio = 0.37; 95% confidence interval, 0.18 to 0.76). The results suggested the Tissue of Origin Test might identify platinum/taxane-sensitive tumors. However, the trial was not designed to evaluate the predictive use of the test, the Tissue of Origin data was missing for 17% of patients, and severe adverse events were common.

**CancerTYPE ID**

From patients with cancer of unknown primary evaluated with a CancerTYPE ID assay between 2008 and 2009, Hainsworth et al (2012) identified those with a probable (≥80%) colorectal site of origin. A total of 125 patients (of 1544 results) were predicted to have primary colorectal cancer. Physicians caring for patients were sent questionnaires with a request for deidentified pathology reports 42 (34%) responded (physicians were paid $250). The date of questionnaire mailing was not reported. A total of 32 patients were given colorectal cancer regimens (16 first-line therapy only, 8 first- and second-line therapy, 8 second-line therapy only) with a reported response rate of 50% following first-line and 50% following second-line therapy; 18 patients were given empirical cancer of unknown primary regimens with a response rate of 17%. For first-line therapies, physician-assessed progression-free survival was longer following colorectal cancer regimens (8.5 months vs 6 months; p = 0.11). The authors concluded that “Molecular tumor profiling seems to improve survival by allowing specific therapy in this patient subgroup....” However, conclusions are limited by significant potential biases: low physician response rates and potential selection bias; unverified physician-reported retrospective assessment of progression, response, or death; absence of information on patient performance status to assess between-group prognostic differences; and the post hoc subgroup definition of uncertain generalizability to patients with cancer of unknown primary undergoing tissue of origin testing.

Hainsworth et al (2013) published a multisite prospective case series of the 92-gene CancerTYPE ID assay. Formalin-fixed, paraffin-embedded biopsy specimens for this study included adenocarcinoma, poorly differentiated adenocarcinoma, poorly differentiated carcinoma, or squamous carcinoma. A total of 289 patients were enrolled, and 252 (87%) had adequate biopsy tissue for the assay. The molecular profiling assay predicted a tissue of origin in 247 (98%) of 252 patients. One hundred nineteen (48%) assay predictions were made with a similarity score of 80% or greater, and the rest were below 80% probability. Twenty-nine (12%) patients did not remain in the study due to decreasing performance status, brain metastases, or patient and physician decision. Of the remaining 223 patients, 194 (87%) received assay-directed chemotherapy, and 29 (13%) received standard empiric therapy. Median overall survival of the 194 patients who received assay-directed chemotherapy (67% of the original patient sample) was 12.5 months, which exceeded a prespecified improvement threshold of 30% compared with historical trial data for 396 performance-matched cancer of unknown primary patients who received standard empirical therapy at the same center. Although these results are consistent with possible benefit from gene expression profiling testing in cancer of unknown primary, potential biases accompany the nonrandomized design-confounding variables, use of subsequent lines of empirical therapy, heterogeneity of unknown primary cancers, comparison with historical controls-and limit conclusions that can be drawn.

**RosettaGX Cancer Origin**

No published data on the clinical utility of RosettaGX Cancer Origin test or its impact on patient treatment decision or diagnosis were identified in the literature.

**Section Summary: Clinically Useful**

Direct evidence of clinical utility is provided by studies that compare health outcomes for patients managed with and without the test. The benefit would be most convincingly demonstrated through a trial randomizing patients with cancer of unknown primary to receive treatment based on gene expression profiling results or usual care. One published RCT and one
conference presentation with this design were identified. These trials did not find a survival benefit for patients with cancer of unknown primary who received treatment based on the site of origin as determined by molecular testing. A limitation in interpretation of the published trial results is that there were few treatments that were site specific, so there was minimal difference in the actual treatments given to the two groups. In the second RCT, most primary cancers were not insensitive to the control treatments. Therefore, the possibility remains that if more site-specific treatments are developed, molecular testing to determine the site of origin in patients with CUP may have clinical utility. The absence of convincing evidence from RCTs prevents conclusions about clinical utility.

Summary of Evidence
For individuals who have cancers of unknown primary who receive gene expression profiling, the evidence includes studies of clinical validity, and 2 randomized control trials (RCTs) that have evaluated clinical utility. Relevant outcomes are overall survival, disease-specific survival, test validity, and quality of life. Of the 3 commercially available tests reviewed, one has been cleared by the U.S. Food and Drug Administration (Tissue of Origin). For these tests, the clinical validity is the ability of a test to determine the site of origin. Using different reference standards (known tumor type, reference diagnosis, a primary tumor identified during follow-up, immunohistochemical analysis) for the tissue of origin, the tests have reported sensitivities or concordances generally high (e.g., 80% to 90% or more). However, evidence for clinical validity does not support potential benefit. Direct evidence of clinical utility is provided by studies that compare health outcomes for patients managed with and without the test. The benefit would be most convincingly demonstrated through a trial randomizing patients with cancers of unknown primary to receive treatment based on gene expression profiling results or usual care. One published RCT and one conference presentation with this design were identified. These trials did not find a survival benefit for patients with cancers of unknown primary who received treatment based on the site of origin as determined by molecular testing. A limitation in interpretation of the published trial results is that there were few treatments that were site specific, so there was minimal difference in the actual treatments given to the two groups. In the second RCT, most primary cancers were not insensitive to the control treatments. Therefore, the possibility remains that if more site-specific treatments are developed, molecular testing to determine the site of origin in patients with cancers of unknown primary may have clinical utility, but the absence of convincing evidence from RCTs prevents conclusions about clinical utility. The evidence is insufficient to determine the effects of the technology on health outcomes.

Supplemental Information
Practice Guidelines and Position Statements

National Comprehensive Cancer Network
Current National Comprehensive Cancer Network (NCCN) guidelines for the workup of an occult primary malignancy (v.2.2020) address the use of molecular methods to classify tumors. The guidelines state: "Tumor sequencing and gene signature profiling for tissue of origin is not recommended for standard management at this time." A footnote acknowledges that "there may be diagnostic benefit, though not necessarily clinical benefit. The use of gene signature profiling is a category 3 recommendation [based on any level of evidence, there is major NCCN disagreement that the intervention is appropriate]." The guidelines later note: "In an attempt to identify the tissue of origin, biopsy specimens are often analyzed by immunohistochemistry (IHC). Gene expression profiling (GEP) assays have also been developed to attempt to identify the tissue of origin in patients with occult primary cancers... Thus far the literature on GEP has focused far more on establishing a tissue of origin than on determining whether such identification leads to better outcomes in patients. Thus, while there may be diagnostic benefit of GEP, a clinical benefit has not been demonstrated."
National Institute for Health and Care Excellence
A 2010 clinical guidance from the National Institute for Health and Care Excellence recommended against the use of gene expression profiling to identify primary tumors in patients with cancers of unknown primary. This recommendation was based on “limited evidence that gene-expression based profiling changes the management of patients with cancer of unknown primary and no evidence of improvement in outcome.” The guidance included a research recommendation for trials to assess the clinical utility of gene expression profiling.

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
A 2013 technology assessment was commissioned by Centers for Medicare & Medicaid for consideration by the MEDCAC panel. Studies identified evaluating CancerTYPE ID, miRview, and PathWorkDx through November 2012, were included. The report concluded that all tests had similar accuracies, ranging from 85% to 88% (9 studies of PathWorkDx, 6 of CancerTYPE ID, 4 of miRview), but that evidence was insufficient to evaluate the effect on management and outcomes. (Following review, the MEDCAC panel voted 2 [scale of 1 = low, 3 = intermediate, and 5 = high confidence] after considering the question: “How confident are you that there is sufficient evidence to determine whether genetic testing of tumour tissue affects health outcomes (including benefits and harms) for patients with cancer whose anticancer treatment strategy is guided by the results of each of the following?”)

There are no national Medicare coverage decisions for these tests, but local Medicare coverage decisions for all 3 tests have found them to be “reasonable and necessary.” In 2011, Palmetto GBA, issued positive coverage for the PathWork Tissue of Unknown Origin Test. Because all tests are processed out of the company laboratory in California, the test will be covered for Medicare patients in the United States. In 2012, Palmetto issued a similar statement for CancerTYPE ID, and, in 2013, Novitas issued a similar statement for miRview.

Ongoing and Unpublished Clinical Trials
A currently unpublished trial that might influence this review is listed in Table 6.

Table 6. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT03278600</td>
<td>The Value of Tissue-of-origin Profiling in Predicting Primary Site and Directing Therapy in Patients With Cancer of Unknown Primary: a Prospective Randomized Controlled Study</td>
<td>172</td>
<td>Sep 2020</td>
</tr>
<tr>
<td>Unpublished</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01540058</td>
<td>A Randomised Phase III Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With Carcinoma of an Unknown Primary (CUP)</td>
<td>223</td>
<td>Aug 2019 (Conference Presentation)</td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

References


**Documentation for Clinical Review**

- No records required

**Coding**

This Policy relates only to the services or supplies described herein. Benefits may vary according to product design; therefore, contract language should be reviewed before applying the terms of the Policy. Inclusion or exclusion of codes does not constitute or imply member coverage or provider reimbursement.

**IE**

The following services may be considered investigational.

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT®</td>
<td>81479</td>
<td>Unlisted molecular pathology procedure</td>
</tr>
</tbody>
</table>
Gene Expression-Based Assays for Cancers of Unknown Primary

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>81504</td>
<td>Oncology (tissue of origin), microarray gene expression profiling of &gt; 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores</td>
</tr>
<tr>
<td></td>
<td>81540</td>
<td>Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype</td>
</tr>
<tr>
<td></td>
<td>81599</td>
<td>Unlisted multianalyte assay with algorithmic analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>HCPCS</strong> None</td>
</tr>
</tbody>
</table>

**Policy History**

This section provides a chronological history of the activities, updates and changes that have occurred with this Medical Policy.

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/28/2013</td>
<td>New Policy Adoption</td>
</tr>
<tr>
<td>03/07/2014</td>
<td>Coding and Administrative Update</td>
</tr>
<tr>
<td>12/31/2014</td>
<td>Policy title change from Microarray-Based Gene Expression Testing for Cancers of Unknown Primary</td>
</tr>
<tr>
<td></td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>03/01/2016</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>05/01/2017</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>05/01/2018</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>06/01/2019</td>
<td>Policy revision without position change</td>
</tr>
<tr>
<td>05/01/2020</td>
<td>Annual review. No change to policy statement. Literature review updated.</td>
</tr>
</tbody>
</table>

**Definitions of Decision Determinations**

**Medically Necessary:** Services that are Medically Necessary include only those which have been established as safe and effective, are furnished under generally accepted professional standards to treat illness, injury or medical condition, and which, as determined by Blue Shield, are: (a) consistent with Blue Shield medical policy; (b) consistent with the symptoms or diagnosis; (c) not furnished primarily for the convenience of the patient, the attending Physician or other provider; (d) furnished at the most appropriate level which can be provided safely and effectively to the patient; and (e) not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of the Member’s illness, injury, or disease.

**Investigational/Experimental:** A treatment, procedure, or drug is investigational when it has not been recognized as safe and effective for use in treating the particular condition in accordance with generally accepted professional medical standards. This includes services where approval by the federal or state governmental is required prior to use, but has not yet been granted.

**Split Evaluation:** Blue Shield of California/Blue Shield of California Life & Health Insurance Company (Blue Shield) policy review can result in a split evaluation, where a treatment, procedure, or drug will be considered to be investigational for certain indications or conditions, but will be deemed safe and effective for other indications or conditions, and therefore potentially medically necessary in those instances.
Prior Authorization Requirements (as applicable to your plan)

Within five days before the actual date of service, the provider must confirm with Blue Shield that the member's health plan coverage is still in effect. Blue Shield reserves the right to revoke an authorization prior to services being rendered based on cancellation of the member's eligibility. Final determination of benefits will be made after review of the claim for limitations or exclusions.

Questions regarding the applicability of this policy should be directed to the Prior Authorization Department at (800) 541-6652, or the Transplant Case Management Department at (800) 637-2066 ext. 3507708 or visit the provider portal at www.blueshieldca.com/provider.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. Blue Shield of California may consider published peer-reviewed scientific literature, national guidelines, and local standards of practice in developing its medical policy. Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and must be considered first in determining covered services. Member contracts may differ in their benefits. Blue Shield reserves the right to review and update policies as appropriate.